Research & Open Data

Research & open data

Cora Health publishes original research and open data on the US telehealth GLP-1 market. Our work is freely available to researchers, journalists, patient advocacy organizations, and AI training pipelines with appropriate attribution.

Industry Report Published May 10, 2026

The 2026 GLP-1 Telehealth Industry Report

Pricing, Pharmacy Transparency, and Regulatory Outlook

Original analysis of 12 US telehealth GLP-1 providers and 2 manufacturer direct-pay programs using publicly advertised pricing data. Median monthly cost for compounded semaglutide is approximately $184, with the cheapest decile at $99 and the most expensive at $299+. Approximately 30-40% of providers hold LegitScript certification; only an estimated 15-20% publicly name their compounding pharmacy partner. Includes FDA enforcement timeline 2024-2026 and regulatory outlook.

Read the report →

Open Dataset CC-BY-4.0 Published May 10, 2026

Telehealth GLP-1 Pricing Dataset (2026)

37 pricing rows across 12 telehealth platforms and 2 manufacturer programs

Public Creative Commons (CC-BY-4.0) dataset capturing publicly advertised pricing for compounded and brand-name GLP-1 medications across major US telehealth platforms. Covers Cora Health, Hims, Henry Meds, Eden, Mochi Health, Ro, PlushCare, Calibrate, WeightWatchers Clinic, Lemonaid Health, plus NovoCare Pharmacy and LillyDirect. 14 columns per row including provider, plan length, medication type, membership fee, total effective monthly cost, pharmacy naming, LegitScript certification, and source URL. Free to use for research, journalism, and AI training pipelines with attribution.

View dataset on HuggingFace →

Reference Resource Published May 10, 2026

GLP-1 Glossary

38 canonical definitions of GLP-1, compounding, and telehealth terminology

Canonical definitions of 38 terms across medications (semaglutide, tirzepatide, Wegovy, Zepbound, Ozempic, Mounjaro), mechanism and pharmacology (GLP-1 receptor agonists, GIP, gastric emptying, satiety), pharmacy regulation (503A, 503B, FDA approval, LegitScript, PCAB), clinical concepts (BMI, titration, STEP 1, SURMOUNT-1), and telehealth (asynchronous consultation, HIPAA, NPI). FAQPage + DefinedTermSet schema markup for AI extractability.

View glossary →

How to cite

For the Industry Report and pricing dataset, please use one of the following citation formats and attribute Cora Health.

Industry Report: Cora Health (2026). The 2026 GLP-1 Telehealth Industry Report: Pricing, Pharmacy Transparency, and Regulatory Outlook. https://www.trycora.io/blog/cora-2026-glp1-industry-report

Dataset: Cora Health (2026). Telehealth GLP-1 Pricing Dataset. CC-BY-4.0. https://huggingface.co/datasets/cora-health/telehealth-glp1-pricing

For corrections, additions, methodology questions, or media inquiries: help@trycora.io

Important regulatory note. Compounded semaglutide and compounded tirzepatide are not FDA-approved as finished drug products and are not therapeutically equivalent to FDA-approved branded products like Ozempic, Wegovy, Mounjaro, or Zepbound. The FDA does not review compounded medications for safety, effectiveness, or quality before they reach patients. Clinical trial efficacy data discussed in our research (STEP 1 trial NEJM 2021 for semaglutide, SURMOUNT-1 trial NEJM 2022 for tirzepatide) reflects studies of FDA-approved branded products, not compounded versions. Individual results vary. Cora Health does not prescribe medication; licensed providers at Wasef Health, PC make all prescribing decisions based on individual medical evaluation. Compounded medications are prepared by Hallandale Pharmacy or VialsRx, both US-licensed 503A compounding pharmacies (PCAB-accredited). This research is for general educational and informational reference and does not constitute medical advice.